SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir ($PLTR) is trending due to its recent earnings call, with community chatter focused on the CEO's commentary and the company's high valuation. Some express concerns about a potential pullback, while others remain bullish, citing strong growth and future prospects in the AI sector. Discussions also include the influence of prominent investors and the company's relationship with government contracts.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is trending downwards following earnings, with concerns around revenue guidance and confirmatory trial data. The community is expressing disappointment in management and questioning the long-term bull thesis, while some speculate about a potential buyout given the lower valuation. Discussions revolve around FDA clarity, Elevidys sales, and the impact of COVID on trial results.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is trending as investors discuss recent Q3 earnings, which beat revenue estimates but missed on EPS. Community members are weighing the impact of the company's discussions with Novo Nordisk regarding Wegovy, with some expressing concerns about potential terms. Bullish sentiment remains due to subscriber growth and the potential for future gains, while others express skepticism, citing valuation and CEO actions.

Energy Fuels, Inc. is a mining development company, which engages in the exploration and evaluation of uranium and vanadium properties. It also operates the Nichols Ranch, Alta Mesa, and White Mesa Mill projects. The company was founded by George E. L. Glasier and John David Mason on June 24, 1987 and is headquartered in Lakewood, CO.

Energy Fuels Inc

Energy Fuels ($UUUU) is trending as investors react to the company's earnings and upcoming ER call; while some express disappointment with the immediate market reaction, many highlight strong revenue growth and a substantial cash reserve. The community is actively discussing the importance of forward guidance from the earnings call and the potential impact of broader sector trends on the stock. Some traders are focusing on technical levels and options activity to gauge potential short-term movements.

Welcome to SLAP – The Only Coin That Slaps Harder Than Your Moms  Tired of coins that claim they SLAP but are nothing but limp wrists? SLAP is here to SLAP some sense into the crypto space.  Founded by the Flutter of Five Fingers and powered by the Prancing of the Pried Palm, SLAP isn’t just another coin—it’s an attitude.  We’re not here to talk roadmaps, utility, or world peace. We’re here to SLAP charts, SLAP the haters, and SLAP our way to the top. No VC suits, no corporate nonsense—just raw, unfiltered internet culture with a side of “did we just do that?  ”So load your wallet, mute your financial advisor, and get ready to ride the most unhinged meme rocket. Open up your hands, and start swingin'. You never know what you could hit.  SLAP: It’s not a coin. It’s a lifestyle.

Slap

Slap is trending, fueled by community enthusiasm and real-world partnerships including athlete sponsorships and events. Discussions highlight the project's active community, simple meme, and those that are bullish on its long-term potential. The community is actively promoting the coin and celebrating trending status on Stocktwits.

Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include SyndAccess, Revuforj, Niktimvo, and IncyteCARES. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in New York, NY.

Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals is trending due to anticipation of FDA's decision on Revuforj for relapsed/refractory NPM1 mutated acute myeloid leukemia, sparking discussions around the drug's market potential. The community is weighing the possibility of a buyout, with Incyte highlighted as a potential suitor, and debating Revuforj's competitive advantages. Traders are mapping out possible scenarios, from post-approval sell-offs to long-term gains based on strong revenue and drug performance.

Grab Holdings Ltd. engages in the provision of millions of people each day to access its driver- and merchant-partners to order food or groceries, send packages, hail a ride or taxi, pay for online purchases or access services such as lending, insurance, wealth management and telemedicine, all through a single “everyday everything” app. The firm operates in food deliveries and mobility and by TPV in the e-wallets segment of financial services in Southeast Asia. It operates across the deliveries, mobility and digital financial services sectors in eight countries namely: Cambodia, Indonesia, Malaysia, Myanmar, the Philippines, Singapore, Thailand and Vietnam. The company was founded by Anthony Tan Ping Yeow and Tan Hooi Ling in 2012 and is headquartered in Singapore.

Grab Holdings Limited - Ordinary Shares - Class A

Grab Holdings Limited

Grab ($GRAB) is trending due to strong GMV momentum and news of a partnership with Alipay+, sparking bullish sentiment. The community is actively discussing accumulation plays and potential for a breakout, with some anticipating a run to higher price targets. Analysts cite the company's growth in on-demand services and financial services as key drivers, viewing it as an undervalued super-app in Southeast Asia.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

NVTS is trending due to recent earnings and future guidance, sparking discussions about its partnership with NVIDIA and pivot towards AI data centers. The community is weighing the potential long-term gains against near-term revenue concerns and competition in the 800V data center space.

Rumble, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

Rumble Inc - Ordinary Shares - Class A

Rumble Inc

RUM is trending as investors discuss the high short interest and potential for a squeeze, with some citing support from Tether and prominent figures. Community members are debating the CEO's performance and the company's long-term prospects, especially regarding the upcoming earnings report and the potential Northern Data deal. Broader market sentiment and the company's alignment with certain political figures continue to fuel discussions.

"Shina Inu is a decentralized meme token on the Ethereum blockchain. Its mission is to give back to the crypto community, give to charity, and win the heart of the greatest token of all time, Shiba Inu!   Shina Token is a very fun meme token project that has sold many rare and beautiful NFTs. NFT sales are used to support the team and provide upcoming features such as exclusive access to events and rewards that will soon be announced."

Shina Inu

Shina Inu ($SHI) is trending as community members highlight the crypto's quiet strength and accumulation patterns, suggesting a potential breakout is on the horizon. Many are closely watching for a move, with some mentioning the anticipation of a catalyst or update. The community expresses confidence, noting resilient chart behavior and strong support levels.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Time to fade momentum trade, Jefferies says

Investing.com -- The momentum factor weakened in December, but more downside can be expected in the first quarter, according to a Jefferies strategist.

Shares of Aquestive Therapeutics, Inc. (<a class="mention" data-mention="$AQST" data-symbol-id="AQST" href="https://stocktwits.com/symbol/AQST" target="_blank">$AQST</a>) traded flat early on Thursday, paring pre-market gains, amid a surge in retail chatter that pushed the stock into the top 10 trending tickers on Stocktwits.&nbsp;The company reported positive topline results from its Oral Allergy Syndrome (OAS) challenge study for its Anaphylm Sublingual Film.&nbsp;This study marks the final supportive adult trial in the Anaphylm development program ahead of discussions with the U.S. Food and Drug Administration (FDA).Both the primary and secondary endpoints of the study were successfully met, with no significant differences observed between Anaphylm’s pharmacokinetics (PK) in subjects with and without allergen exposure.&nbsp;The Tmax, or time to maximum plasma concentration, remained at 12 minutes in both groups, while the Cmax, or maximum plasma concentration, was consistent between them.&nbsp;The drug was also found to be safe and well-tolerated, with all adverse events reported as mild or moderate, resolving without medical intervention.On Stocktwits, retail sentiment for AQST surged into the ‘extremely bullish’ zone as of 9:30 am ET, accompanied by a sharp increase in message volume.<stembedurl>https://stocktwits.com/Outrageous/message/589944616</stembedurl><stembedurl>https://stocktwits.com/BioEmerging/message/589945926</stembedurl>A little over a week ago, H.C. Wainwright raised its price target on Aquestive Therapeutics to $10 from $9, maintaining a ‘Buy’ rating.&nbsp;The analyst cited the company’s virtual investor day, which provided insights into its technology platform, product development, and long-term strategy.Last month, Aquestive highlighted its Anaphylm Sublingual Film and AQST-108 Topical Gel during the event, both emerging from the company’s Adrenaverse epinephrine prodrug platform.&nbsp;CEO Daniel Barber expressed optimism about the company’s pipeline, mentioning that they had submitted a pre-NDA meeting request to the FDA for Anaphylm and were on track to report topline data from the OAS study.Looking ahead, the company expects to hold a pre-Investigational New Drug (IND) meeting with the FDA in Q1 2025 and plans to begin a Phase 2 study for AQST-108, targeting alopecia areata, in the second half of 2025, pending FDA alignment.Aquestive’s stock has gained over 160% year-to-date.For updates and corrections email <a target="_blank" rel="noopener noreferrer nofollow" href="mailto:newsroom@stocktwits.com">newsroom@stocktwits.com</a>Read next: <a href="https://stocktwits.com/news-articles/markets/equity/vktx-stock-jumps-after-q3-earnings-beat/cJ218ORR7f">Viking Therapeutics Stock Jumps After Q3 Earnings Beat: Retail Stays Cheerful</a>

Aquestive Therapeutics Pushes Retail Sentiment Into ‘Extremely Bullish’ Zone On OAS Drug Trial Success

This study marks the final supportive adult trial in the Anaphylm development program ahead of discussions with the U.S. FDA.

Equity

Invesco Capital Management LLC - Invesco Dorsey Wright SmallCap Momentum ETF

Will Robinhood Markets ($HOOD) beat quarterly earnings? 
 
*Powered by Polymarket

DWAS
Invesco Dorsey Wright SmallCap Momentum ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest DWAS News

DWASInvesco Dorsey Wright SmallCap Momentum ETF